ASX:4DXHealthcare Services
The Bull Case For 4DMedical (ASX:4DX) Could Change Following CT:VQ Approval And Huge U.S. Market Potential
In February 2026, 4DMedical Limited reported half-year results to 31 December 2025, with sales of A$2.85 million and a net loss of A$154.14 million, alongside basic loss per share from continuing operations of A$0.311 and diluted loss per share of A$0.259.
Despite the wider reported loss, the company highlighted an improved adjusted net loss, strong pro forma cash position, and a newly approved CT:VQ imaging product targeting an initial addressable U.S. market exceeding US$1.10 billion...